Harvard Bioscience (HBIO) EV to FCF (2010 - 2026)

Harvard Bioscience (HBIO) has reported EV to FCF for 17 consecutive years, with 59.21 the latest figure, recorded in Q2 2026.

• On a quarterly basis, EV to FCF fell 1399.05% year-over-year to 59.21 in Q2 2026; TTM through Jun 2026 was 19.21, a 865.2% decrease from a year earlier, with the FY2025 full-year figure at 3.9, up 105.29% from the prior year.
• EV to FCF was 59.21 for Q2 2026 at Harvard Bioscience, down from 13.66 in the prior quarter.
• Over five years, EV to FCF peaked at 490.34 in Q3 2022 and troughed at 229.65 in Q2 2022.
• A 5-year average of 31.95 and a median of 11.27 in 2025 frame the typical range for EV to FCF.
• Across the five-year window, EV to FCF soared 300.14% in 2022 and sank 1399.05% in 2026, its largest moves.
• Over 5 years, EV to FCF stood at 45.85 in 2022, then jumped by 43.1% to 65.61 in 2023, then retreated by 4.86% to 62.42 in 2024, then sank by 162.75% to 39.17 in 2025, then plunged by 51.16% to 59.21 in 2026.
• The last three EV to FCF figures came in at 59.21 (Q2 2026), 13.66 (Q1 2026), and 39.17 (Q4 2025), per Business Quant data.